Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multi-centre, randomized, double blind, placebo-controlled, parallel group study to investigate efficacy and safety of ONO-2506PO compared to placebo, in the presence of riluzole, to patients diagnosed with amyotrophic lateral sclerosis (ALS), who have had onset of muscle weakness within 14 months of randomization.

Next Previous
X
Search
Trial Profile

A multi-centre, randomized, double blind, placebo-controlled, parallel group study to investigate efficacy and safety of ONO-2506PO compared to placebo, in the presence of riluzole, to patients diagnosed with amyotrophic lateral sclerosis (ALS), who have had onset of muscle weakness within 14 months of randomization.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Arundic acid (Primary) ; Riluzole
  • Indications Amyotrophic lateral sclerosis
  • Focus Therapeutic Use
  • Sponsors Ono Pharmaceutical

    • Most Recent Events

    • 11 Dec 2008 Actual trial completion date identified as December 2008 from ClinicalTrials.gov.
    • 11 Dec 2008 Actual trial completion date identified as December 2008 from ClinicalTrials.gov.
    • 11 Dec 2008 Status changed from active, no longer recruiting to completed according to ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top